Balance Sheet
Accounts PayablesCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dr Reddys Laboratories (RDY) Receivables: 2018-2025

Historic Receivables for Dr Reddys Laboratories (RDY) over the last 8 years, with Mar 2025 value amounting to $1.1 billion.

  • Dr Reddys Laboratories' Receivables rose 9.87% to $1.1 billion in Q1 2025 from the same period last year, while for Mar 2025 it was $3.8 billion, marking a year-over-year increase of 11.13%. This contributed to the annual value of $1.1 billion for FY2025, which is 9.87% up from last year.
  • Latest data reveals that Dr Reddys Laboratories reported Receivables of $1.1 billion as of FY2025, which was up 9.87% from $963.0 million recorded in FY2024.
  • Dr Reddys Laboratories' 5-year Receivables high stood at $1.1 billion for FY2025, and its period low was $679.0 million during FY2021.
  • For the 3-year period, Dr Reddys Laboratories' Receivables averaged around $967.7 million, with its median value being $963.0 million (2024).
  • Data for Dr Reddys Laboratories' Receivables shows a peak YoY climbed of 29.60% (in 2022) over the last 5 years.
  • Yearly analysis of 5 years shows Dr Reddys Laboratories' Receivables stood at $679.0 million in 2021, then grew by 29.60% to $880.0 million in 2022, then climbed by 0.23% to $882.0 million in 2023, then grew by 9.18% to $963.0 million in 2024, then increased by 9.87% to $1.1 billion in 2025.